PTPN11 and neoplasm: Systemic SHP2 inhibition increases tumor necrosis, decreases tumor blood vessels and blood perfusion, and promotes tumor vascular system degradation and blood extravasation in animals harboring SHP2-independent tumor cell proliferation of the chosen tumor type.